• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Organisation › Details

GlaxoSmithKline (GSK) (Group)

GlaxoSmithKline- one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. *

 

	Start	2000-12-27 merged
	Predecessor	Glaxo Wellcome (Group)
	Industry	pharmaceutical
	Industry 2	vaccine
	Person	Walmsley, Emma (GSK 201704– CEO before CEO of GSK Consumer Healthcare division joined GSK 2010 from L’Oréal)
	Person 2	Mackay, Iain (GSK 201901– CFO before HSBC + GE + Schlumberger Dowell + Price Waterhouse)
	Region	United Kingdom (town unspecified)
	Country	United Kingdom (GB)
	Street	980 Great West Road
	City	TW8 9GS Brentford, Middlesex
	Tel	+44-0-20-8047-5000
		Address record changed: 2008-12-07
Basic data	Employees	n. a.
	Currency	GBP
	Annual sales	22,716,000,000 (turnover, consolidated (2007) 2007-12-31)
	Profit	7,931,000,000 (2007-12-31)
	Cash	3,379,000,000 (2007-12-31)
		* Document for �About Section�:
		Record changed: 2019-08-13

Advertisement

More documents for GlaxoSmithKline (GSK) (Group)

• [1] GlaxoSmithKline plc. (8/23/19). "Press Release: GSK Announces Positive Headline Results from the Pivotal DREAMM-2 Study for Multiple MMyeloma". London....
• [2] GlaxoSmithKline plc. (8/22/19). "Press Release: ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-treatment Regimen Administered every Two Months". London....
• [3] GlaxoSmithKline plc. (8/21/19). "Press Release: GSK Submits First Regulatory Application for Daprodustat in Japan for Patients with Renal Anaemia Due to Chronic Kidney Disease". London....
• [4] GlaxoSmithKline plc. (8/12/19). "Press Release: GSK Announces Leadership Changes in the US". Philadeliphia, PA....
• [5] GlaxoSmithKline plc. (7/3/19). "Press Release: ViiV Healthcare Receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection". London....
• [6] MorphoSys AG. (7/3/19). "Press Release: MorphoSys' Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019". Planegg....
• [7] GlaxoSmithKline plc. (7/3/19). "Press Release: GSK Announces Phase III Start for Its anti GM-CSF Antibody, Otilimab, in Patients with Rheumatoid Arthritis (RA)". London....
• [8] Antibodies.com. (7/2/19). "Press Release: Antibodies.com Raises £400,000 Pre-Seed Round to Help Researchers Discover More For Less". Cambridge....
• [9] Adaptimmune Therapeutics plc. (6/27/19). "Press Release: Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer". Philadeliphia, PA & Oxfordshire....
• [10] GlaxoSmithKline plc. (6/24/19). "Press Release: U.S. Food and Drug Administration Accepts GSK’s Application for Zejula (niraparib) in Late Stage Ovarian Cancer with Priority Review". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.